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Objectives: To understand why dronedarone failed to unseat amiodarone as the 
primary antiarrhythmic treatment of choice for persistent AF, thus uncovering the 
clinical outcome requirements for a future AF therapy to achieve optimal market 
access. MethOds: Review published HTA reports and clinical trial outcomes for 
dronedarone to assess market access outcomes and associated Payer rationale for 
decision-making. Interview ten (10) managed care medical directors and AF key 
opinion leaders (KOLs) in US and thirteen (13) ex-Payers and AF KOLs in Europe 
(mix of stakeholders encompassing France, Germany, Italy, Spain, and UK) for vali-
dation and gap filling. Results: Driven by benefits in all efficacy outcomes other 
than cardiovascular-related hospitalizations, Payers perceive amiodarone as more 
efficacious than dronedarone. The significant number of deaths during the high-
risk PALLAS study crippled the safety image of dronedarone. Finally, a prohibitive 
price at launch contributed to a multiplicity of negative HTA assessments. In order 
to succeed where dronedarone failed and qualify as a step function increase over 
the standard-of-care amiodarone, Payers require at least: 40% reduction in AF recur-
rence; 30% relative risk reduction in hospitalizations compared to amiodarone; 
and fewer than 1% deaths as part of the clinical evidence package. Lower rates of 
bradyarrhythmia, liver toxicity, and no proarrhythmia will drive a favorable regula-
tory safety evaluation compared to amiodarone. cOnclusiOns: The sub-optimal 
market access and relatively low utilization of dronedarone resulted primarily from 
a failure to demonstrate an improvement in recurrence as compared to amiodar-
one, as well as a significant number of deaths during pivotal trials. Manufacturers 
considering development of novel antiarrhythmics should strive for equivalent 
efficacy but superior safety to amiodarone if a 40% reduction in recurrence is not 
clinically feasible.
PCV116
Assessment Of PAyer Willingess tO PAy fOr nOVel HeArt fAilure 
tHerAPies: inCrementAl imPrOVement in symPtOm relief Versus 
DiseAse mODifying
Proach J., Cromer K., Black J.
Market Access Solutions LLC, Raritan, NJ, USA
Objectives: Existing heart failure standard of care (SoC) provides symptom 
relief with no impact on changing the disease course. This research assessed 
Payers’ perceived value and willingness to pay (WTP) for a novel oral therapy 
with significant improvement on top of SoC and a cell therapy providing poten-
tial disease modifying outcomes and enhanced mortality benefit. MethOds: An 
online survey with 22 US and EU-5 Payers assessing perceptions of current SoC 
therapies was conducted. A systematic evaluation of heart failure pharmaceuti-
cal, biologic and cell based therapies under clinical development was performed 
from which two hypothetical product profiles were developed: 1) a novel orally 
administered therapy; and 2) a recombinant cell based treatment via intramyo-
cardial infusion. Profiles were then tested by 30 in-depth interviews with US and 
EU-5 Payers. Results: Payer preference is based on the technology’s ability to 
meet efficacy targets treating the broadest heart failure patient segments. The 
oral agent was the preferred agent due to the clinical feasibility to develop with a 
WTP per day of US $8, UK £ 3 and EU € 5 based on efficacy: ≥ 28% RRR composite 
of CV death and HF hospitalizations; ≥ 25% RRR in CV mortality and ≥ 25% RRR 
in all-cause mortality. The cell based therapy was cited as the most promising 
by improving symptoms and changing disease course with a WTP per treatment 
of US $6,500, UK £1,200 and EU € 1,000 based on efficacy: improvement of NYHA 
functional class in ≥ 15% of patients in 1 year and ≥ 15% improvement in heart 
function. cOnclusiOns: Payers see novel oral therapies as highly feasible and 
efficient in treating the broadest population and are willing to pay a premium. 
However, technologies that are disease modifying, reduce hospitalizations, and 
provide a significant mortality benefit are most desirable notwithstanding the 
considerable cost of treatment.
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Objectives: Chest pain complaint is a common and difficult condition to diagnose 
due to the diversity of the underlying conditions that could cause it. The objective 
of this study is to examine the impact of the uncertainty in diagnosis on resource 
utilization using chest pain as an example. MethOds: Cross-sectional explora-
tion of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for U.S. 
emergency departments conducted between 2006 and 2010. Patients whom primary 
reason for visiting the ED was chest pain were classified into two categories based 
on the physicians’ final diagnosis upon discharge: 1) well-defined diagnosis and 
2) ill-defined diagnosis(unspecific chest pain(ICD9= 786.5X)). Differences between 
groups in resource utilization which includes the number of procedures, diagnos-
tics and length of visits were examined using bivariate analyses. Results: There 
were 8,662 ER visits, representing more than 33 million ER visits between 2006 and 
2010 where the chief complaint was chest pain. More than half of those patients 
(54%) had an ill-defined diagnosis upon discharge. No difference between the two 
groups were detected in gender (female = 53%), race (72.8% white, 23.6% black and 
3.6% others), education, subsequent hospital admission (30%) and number of pro-
cedures (mean= 0.7, STD= 0.03). Patients with ill-defined diagnosis, however, were 
more likely to be admitted to observation units (5.8% vs. 1.9%, p< 0.001), received 
more blood tests (p< 0.001), diagnostics (p< 0.001), imaging procedures (44.1% vs. 
33.6%, p< 0.001) specifically X-ray (41.8% vs. 31.5%, p< 0.001) and also had higher 
length of visits (269.5 minutes vs. 241.6 minutes, p< 0.001). cOnclusiOns: The 
uncertainty dictated by the nature of chest pain symptom and the wide array of its 
underlying conditions inflict higher burden on the U.S. healthcare system. Better 
diagnostic techniques with higher sensitivity and specificity are badly needed to 
alleviate this issue.
observed claim were excluded. Cumulative rates were estimated for all HF-related 
hospitalizations, cardiovascular (CV) hospitalizations and all-cause hospitalizations, 
within the study period. Results were further categorized by types of insurance, spe-
cifically, commercial and Medicare advantage. Results: A total of 85,938 patients 
met the study criteria of which 68.3% (n= 58,732) had Medicare advantage coverage 
and 31.7% (n= 27,206) had commercial insurance. The mean age was 63 years for 
patients with commercial insurance and 77 for those with Medicare advantage. 
For the total population (commercial + Medicare advantage), the cumulative hos-
pitalization rate, inclusive of the first hospitalization, was 1.07 per patient-year for 
HF-related hospitalizations, 1.16 for CV-related hospitalizations (inclusive of HF) 
and 1.76 for all-cause hospitalizations. Cumulative hospitalization rates for patients 
with commercial insurance were 0.93, 1.00 and 1.52 for HF-related, CV, and all-cause 
hospitalizations, respectively. For patients with Medicare advantage coverage, the 
cumulative hospitalization rates were 1.14, 1.24 and 1.88 for HF-related, CV, and 
all-cause hospitalizations, respectively. cOnclusiOns: Patients with heart failure 
who have been hospitalized have frequent subsequent hospitalizations. On average, 
these individuals were hospitalized at least once a year for worsening heart failure, 
irrespective of their coverage.
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Objectives: To assess health care resource utilization and costs among U.S. 
patients diagnosed with cardiovascular disease (CVD) using the Veterans Health 
Administration (VHA) dataset. MethOds: Patients diagnosed with CVD or who 
underwent CVD-related procedures were identified (International Classification 
of Disease, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis codes 410, 412, 
411.1, 411.81, 411.89, 434, 436, 437.0, 437.1, 438, 997.02, 435 and 428, ICD-9 procedure 
codes 00.66, 36.09 and current procedural terminology [CPT]-4 codes 33503-33545) 
using the VHA dataset from 01OCT2008 through 30SEPT2012. The initial diagnosis 
date was designated as the index date. Patients without a CVD diagnosis, who were 
of the same age, race and gender as study CVD patients, were identified for com-
parison. An index date was selected at random to minimize bias. Patients in both 
groups were required to be age ≥ 18 years with continuous medical and pharmacy 
benefits 1 year pre- and post-index date. One-to-one propensity score matching 
(PSM) was used to compare health care resource utilization and costs between the 
CVD and comparison groups during the follow-up period, adjusting for baseline 
demographic and clinical characteristics. Results: After risk-adjusted analysis 
using PSM, 536,125 patients in each group were matched. More CVD patients had 
inpatient admissions (14.40% vs. 1.43%, p< 0.0001) and emergency room (14.89% 
vs. 3.66%, p< 0.0001), outpatient office (60.90% vs. 47.19%, p< 0.0001), outpatient 
(61.35% vs. 47.99%, p< 0.0001) and pharmacy visits (64.41% vs. 54.89%, p< 0.0001) 
compared to those without CVD. CVD patients also incurred higher costs. Costs 
were significantly higher for CVD patients than for those without CVD ($8,248 
vs. $1,638, p< 0.0001). cOnclusiOns: CVD patients in the VHA population more 
frequently utilized health care resources and incurred higher costs than those 
without CVD.
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Objectives: By estimating the direct medical cost of hemorrhagic stroke inpatients 
with urban basic health insurance scheme(exclude new rural cooperative medical care 
system )from 2010 to 2012 in China, we try to provide evidence for the government to 
manage the illness more effectively. MethOds: The inpatients with discharge diag-
nosis disease coded with ICD-10 (I60,I61,I62) were extracted from the China Health 
Insurance Research Association claim database which includes a nationwide, cross-
sectional sampling of inpatients from 2010 to 2012.In this paper, the descriptive statis-
tical analysis was used. Results: The analysis included 6715 patients(male:63.49%), 
patients with older than 50 years accounted for 82.87%(n= 5565). From 2010 to 2012, 
the average hospitalization expenses of each visits were 24656.0,23131.4 and 24995.0 
yuan(the average hospitalization expenses in the whole country:8849,8852and 9732 
yuan).Third-level hospitals, second-level hospitals and under second-level hospitals 
accounted for 57.85%,34.22% and 9.41%, respectively; total hospitalization expenses 
accounted for 71.35%, 22.69% and 5.85%; the average hospitalization expenses were 
30303.49, 16446.19 and 18624.96 yuan.78.78% of inpatient hospital expenses were 
occupied by patients who were over 50 years old. Reimbursement by urban basic 
health insurance scheme in 2010, 2011 and 2012 was 66.47%, 70.59% and 65.08%, 
respectively; while the corresponding patient co-pay burden was 33.53%, 29.41% and 
34.92%. cOnclusiOns: The average hospitalization expenses of each visits of hem-
orrhagic stroke was greater than the national average inpatients costs, although the 
reimbursement by urban basic health insurance scheme had increase dramatically, 
but the out-of-pocket spending was still high, especially for the poor.60% of inpatients 
went to third-level hospital, needing to establish patient grading care system at once, 
going back to community hospitals after recovery, which may reduce the burden of 
medical institutions and patients .
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37.76% and 11.31%. From 2010 to 2012, the average hospitalization expenses of 
each visit with BMISE was 25575.34, 24219.22 and 26889.57 yuan; For BMISUR, the 
expenses of each visit was 21211.57, 18999.53 and 19088.96 yuan. Reimbursement by 
BMISE in 2010, 2011 and 2012 was 71.01%, 74.12% and 68.25%; while the reimburse-
ment by BMISUR was 45.95%, 53.49% and 51.16%. cOnclusiOns: The insurance 
level difference between two health insurance schemes influences the treatment 
regimens and benefits received by patients. People prefer to go to third-level hospi-
tals, but people with BMISE has higher proportion than people with BMISUR, about 
10%. For the people with BMISUR, the out-of-pocket spending was 50% of total 
expenses, needing to raise reimbursement rate, setting up differentiated reimburse-
ment for different income level groups. From 2011 to 2012, the reimbursement rate 
declined slowly, we need to study the cause in the future.
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Objectives: According to Canada, US and European guidelines and the Helsingborg 
Declaration, all eligible stroke patients should receive care in specialized stroke 
centers. During the last decade, partly due to the Alberta Provincial Stroke Strategy 
(APSS), 16 stroke centers were established in Alberta. This study examined the effect 
of admission to stroke centers on mortality for patients with ischemic stroke, com-
pared with admission to non-stroke centers. MethOds: The study population was 
identified from the Discharge Abstract Database (DAD) from the province of Alberta, 
Canada. We included stoke patients with most response diagnostic code I63 (ICD10) 
with a first admission to acute care hospitals between April 1st 2004 and March 
31st 2011. Disease specific co-morbidities were adapted from the literature review, 
including secondary diagnoses in the DAD. We utilized the triage information from 
National Ambulatory Care Report System (NACRS) as the proxy of disease severity. 
The average marginal effect of stroke center on the 30-days in-hospital mortality 
was estimated in a bivariate probit model, using differential distance to hospitals as 
an instrumental variable to correct potential pre-hospital selection bias, adjusting 
for age, sex, co-morbidities, and disease severity. Results: Among 9152 patients, 
6405 (70%) were admitted to stroke centers (n= 16) and 2747 (30%) to non-stroke 
centers. The overall unadjusted 30-day all-cause mortality rate was 9.8% for patients 
first admitted to stroke centers and 11.1% for patients admitted to non-designated 
hospitals. Adjusting patient characteristics and other factors, we found first admis-
sion to a stroke center was associated with a 6.4% (95%CI: -1.2%, -11.5%) absolute 
reduction in 30-day all-cause in-hospital mortality compared to non-stroke cent-
ers. cOnclusiOns: In an observational study, we provided new evidence to sup-
port the role of stroke center on the reduction in mortality in a universal publicly 
funded health care system.
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Objectives: Although previous studies have shown that stroke centers reduce 
mortality in patients with ischemic stroke, the association between stroke cent-
ers and reduction in length of stay (LOS) in hospital has not been demonstrated. 
We sought to evaluate the impact of stroke centres as designated by the Alberta 
Provincial Stroke Strategy (APSS) in Alberta on the LOS of acute ischemic stroke 
patients. MethOds: We compared the actual LOS during the first episode of hos-
pitalization for patients with acute ischemic stroke admitted first to designated 
stroke centers or non-stroke centers between April 1st 2004 and March 31st 2011 
using the Alberta Hospital Discharge Abstracts Database. Using propensity score 
methods, we applied a log linear regression model to estimate the average change 
in LOS for all ischemic patients and the change for the patients admitted to the 
stroke centers, adjusting for age, sex, co-morbidities, disease severity, discharge 
type and being in the alternate level of care. Results: Among 9,092 patients, 6,360 
(70%) were admitted to stroke centers. The prolonged hospital stay with alternate 
level of care designation had occurred in 1,572 (17.3%) of patients. The number of 
patients discharged to home, home with support or other health care facility, or 
died were 3,767(41.4%) 4,159(45.7%), and 1,166 (12.8%), respectively. The average 
unadjusted LOS was 21.3 (SD= 33.9) days for patients admitted to stroke centers 
and 24.8 (SD= 37.5) days for patients admitted to non-stroke centers. Adjusting 
for the patient characteristics and other factors, we estimated that the average 
LOS was reduced by 6.5% (95%CI: -12.3%, -0.6%) for patients first admitted to 
stroke centers compared with non-stroke centers. cOnclusiOns: The study 
shows that in patients with acute ischemic stroke, first admission to stroke cent-
ers had significantly reduced LOS compared with non-stroke centers in Alberta 
by about 1.4 days.
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Objectives: Medicaid coverage among non-elderly adults is often characterized by 
drop-outs and churning – entering and exiting Medicaid – over short durations. Little 
is known about the impact of such disruptions in Medicaid coverage on health care 
resources utilization and adherence to cardiovascular and lipid-lowering medica-
tions among enrollees with cardiovascular disease (CVD). MethOds: This was a 
retrospective, repeated cross-sectional study design employing data from 2002-2011 
Medical Expenditure Panel Survey. Study sample included adults aged 18-64 years 
diagnosed with ≥ 1 CVD or associated comorbidity who reported having Medicaid 
coverage any time during survey year. Individuals with CVD having continuous, full-
year Medicaid coverage (N= 1,624) were compared to those with < 12 months of cov-
erage (N= 3,394). Medication adherence was calculated as proportion of days covered 
by refills of any CVD medication class examined during the reference period, capped 
at 1, and analyzed using ordinary least squares regression and multivariate logistic 
regression. Utilization of 5 CVD-specific health care resources – inpatient, emer-
gency (ER), outpatient, and office-based physician visits, and prescription medica-
tions – were estimated using zero-inflated negative binomial models controlling for 
sociodemographic, health status, disease burden, and Medicaid eligibility covariates, 
and year fixed effects. Results: Older age, White race, higher income, intermit-
tent employment, any private insurance were significant predictors of Medicaid 
discontinuity (P< 0.05). Individuals experiencing discontinuity in Medicaid coverage 
were predicted to have 0.03 more inpatient (P< 0.01), 0.03 more ER (P< 0.001), and 0.24 
less office-based physician visits (P< 0.05), and 0.02 more prescription medications 
(P< 0.05), all other things being equal. Medication adherence was not significantly 
different between the two groups, nor was it a significant predictor in most outcome 
models. cOnclusiOns: Individuals with CVD having discontinuous Medicaid cov-
erage had higher hospital, and lower primary care utilization than their counterparts 
with continuous Medicaid coverage. Medicaid programs will greatly benefit from 
implementing provisions that mitigate coverage instability and associated disrup-
tions in continuity of care.
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Objectives: Diabetic nephropathy is the leading cause of chronic kidney dis-
ease in the United States and is associated with increased mortality. A quality 
measure that contributes to a CMS Star Rating is that patients with hypertension 
and diabetes receive a renin-angiotensin system (RAS) inhibitor. The objective 
of this study was to compare the impact of a Diabetes Treatment Management 
(DTM) Program, aimed to improve the compliance of appropriate RAS inhibitors 
for diabetic patients, between dual eligible (DE) and non-DE Medicare Advantage 
beneficiaries. MethOds: This was a retrospective study of pharmacy claims data 
among Medicare Advantage beneficiaries > 18 years of age in 2014. Members with 
one diabetic medication claim and one anti-hypertensive medication (calcium 
channel blockers or beta blockers) claim were included. The DTM program alerted 
the prescribing provider via fax to add a CMS recommended RAS inhibitor, if appro-
priate. Intervention success was defined when a recommended anti-hypertensive 
medication (renin angiotensin system antagonist, angiotensin converting enzyme, 
angiotensin receptor blocker, or direct renin inhibitor) was subsequently filled by 
the targeted member. Comparisons between groups were performed using the χ 2 
test. Results: This data represents 1,037,543 non-DE and 195,413 DE Medicare 
Advantage beneficiaries. A total of 32,154 members were eligible for the DTM 
program. Of these, 26,896 (84%) were among non-DE and 5,258 (16%) were among 
DE Medicare beneficiaries. The DTM program was successful in 26% of the overall 
population. The success rate was 27% (7,177/26,896) among non-DE compared 
to 23% (1,211/5,258) among DE Medicare beneficiaries receiving the intervention 
(p< 0.0001). cOnclusiOns: The DTM program was more successful in the non-
DE than in the DE Medicare Advantage population. However, further research 
is needed to understand the factors behind the difference in success for these 
populations.
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Objectives: The study aimed to compare the direct medical cost difference of 
hemorrhagic stroke inpatients with different types of health insurance from 2010 to 
2012 in China. MethOds: A nationwide, cross-sectional sampling of hemorrhagic 
stroke inpatients with disease code ICD-10 (I60,I61,I62) with basic medical insurance 
scheme for employees (BMISE) and basic medical insurance scheme for urban resi-
dents (BMISUR) was extracted from the China Health Insurance Research Association 
claim database. A retrospective analysis was adopted. Results: The inpatients 
number of BMISE was 5321,the inpatients number of BMISUR was 1510. The average 
age was 63.08 and 62.34 years, respectively. Patients with BMISE went to third-level 
hospitals, second-level hospitals and under second-level hospitals accounted for 
57.01%, 33.71% and 9.27%; but for BMISUR, the percentage of distribution was 48.94%, 
